Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

An Open Label, Phase 2 Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Sebastian Grosicki, MD PhD, Genadi Iosava, MD, Mamia Zodelava, MD, Nikolay Tzvetkov, MD, Tadeusz Robak, MDPhD, Atanas Radinoff, MD, Kasi Viswanath Routhu, PhD, Prajak Barde, MD, Ajit Mohanchandran Nair, PhD

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-136031

Published: 2020

Journal Articles

Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Paul A. Hamlin, MD, Vasile Musteata, MD PhD, Mamia Zodelava, MD, Steven I Park, MD, Christine Burnett, Kristina Dabovic, PharmD, Eric T Williams, PhD, Jack P Higgins, PhD, Daniel O. Persky, MD

Blood (2019) 134 (Supplement_1): 4098.

https://doi.org/10.1182/blood-2019-129243

Published: 2019

Journal Articles

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Daniel O. Persky, MD, Vasile Musteata, MD PhD, Mamia Zodelava, MD, Tetiana Perekhrestenko, MD PhD, Adolfo E Diaz, MD, Troy H. Guthrie, Jr., MD, Thomas Strack, MD, Christine Burnett, Sarah Wilson, CCRA, Tara Baetz, MD FRCPC

Blood (2019) 134 (Supplement_1): 5324.

https://doi.org/10.1182/blood-2019-128604

Published: 2019

Journal Articles

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Jorge Cortes, MD, James Foran, MD, Darejan Ghirdaladze, MD, PhD, Marcel P DeVetten, MD, Mamia Zodelava, MD, PhD, Peter Holman, MD, Mark J Levis, MD, PhD, Hagop M Kantarjian, MD, Gautam Borthakur, MD, Joyce James, PhD, Patrick P Zarringkar, PhD, Ruwanthi N Gunawardane, PhD, Robert C Armstrong, PhD, Norman M Padre, Wendell Wierenga, PhD, Robert Corringham, MD, Mohit Trikha, PhD

Blood (2009) 114 (22): 636.

https://doi.org/10.1182/blood.V114.22.636.636

Published: 2009

Journal Articles

Forodesine (Fodosine TM ), a PNP Inhibitor Active in Relapsed or Refractory T-Cell Leukemia Patients (Phase II Study).

Richard R. Furman, MD, Genadi Iosava, MD, Luis Isola, MD, Farhad Ravandi, MD, Mamia Zodelava, MD, J. Claude Bennett, MD, J. Michael Kilpatrick, PhD, Shanta Bantia, PhD, Fodosine Development Group

Blood (2005) 106 (11): 881.

https://doi.org/10.1182/blood.V106.11.881.881

Published: 2005

NARROW

An Open Label, Phase 2 Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Forodesine (Fodosine TM ), a PNP Inhibitor Active in Relapsed or Refractory T-Cell Leukemia Patients (Phase II Study).

Email alerts

ASH Publications

American Society of Hematology

An Open Label, Phase 2 Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Forodesine (Fodosine TM ), a PNP Inhibitor Active in Relapsed or Refractory T-Cell Leukemia Patients (Phase II Study).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only